NDA 021951 · Sun Pharm Inds INC
Absorica
Isotretinoin · Oral · Retinoid
Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
May 25, 2012
Approved uses
1
Original approval plus efficacy supplements
Registered trials
179
33 Phase 3, 11 recruiting
FAERS reports
18,655
9,780 serious, 453 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY – CONTRAINDICATED IN PREGNANCY ABSORICA/ABSORICA LD can cause life-threatening birth defects and is contraindicated in pregnancy. There is an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking any amount of ABSORICA/ABSORICA LD even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining prenatally whether an exposed fetus has been affected. If pregnancy occurs, discontinue ABSORICA/ABSORICA LD immediately and refer the patient to an Obstetrician- Gynecologist experienced in reproductive toxicity for further evaluation and counseling [see Contraindications (4) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.1) ]. Because of the risk of embryo-fetal toxicity, ABSORICA and ABSORICA LD are available only through...
What it is approved for
From the label in effect Aug 19, 2026.
ABSORICA and ABSORICA LD are indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, ABSORICA and ABSORICA LD are reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. Limitations of Use If a second course of ABSORICA/ABSORICA LD treatment is needed, it is not recommended before a 2-month waiting period because the patient’s acne may continue to improve following a 15 to 20-week course of treatment [see Dosage and Administration (2.2) ]. ABSORICA and ABSORICA LD are retinoids indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, ABSORICA and ABSORICA LD are reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. (1) Limitations of Use: If a second course of ABSORICA/ABSORICA LD treatment is needed, it is not recommended before a two-month waiting period because the patient’s acne may continue to improve following a 15 to 20-week course of treatment. (1)
Mechanism: The exact mechanism of action of ABSORICA/ABSORICA LD in the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater who are unresponsive to conventional therapy, including systemic antibiotics is unknown. ABSORICA/ABSORICA LD is a retinoid, which inhibits sebaceous gland function and keratinization. Clinical improvement in nodular acne patients occurs in association with a reduction in sebum secretion. The decrease in sebum secretion is temporary and reflects a reduction in...
Therapeutic areas: Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
6 products under this application
- ABSORICA · ISOTRETINOIN 35MG · CAPSULE, ORAL · Prescription · TE AB2
- ABSORICA · ISOTRETINOIN 40MG · CAPSULE, ORAL · Prescription · TE AB2
- ABSORICA · ISOTRETINOIN 20MG · CAPSULE, ORAL · Prescription · TE AB2
- ABSORICA · ISOTRETINOIN 25MG · CAPSULE, ORAL · Prescription · TE AB2
- ABSORICA · ISOTRETINOIN 30MG · CAPSULE, ORAL · Prescription · TE AB2
- ABSORICA · ISOTRETINOIN 10MG · CAPSULE, ORAL · Prescription · TE AB2
Clinical trials
Interventional ClinicalTrials.gov studies with "Isotretinoin" as an intervention, any sponsor and status, largest first.
- Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)Pivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT04353180 · 100,000 participants (planned) · Start Aug 2021 · Primary completion Oct 2021
Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment; Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment and 3 more · For: COVID19
Sites: Cairo, Egypt · 2 sites in all
- Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.Pivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT05002530 · 10,000 participants (planned) · Start Nov 2021 · Primary completion Dec 2021
Drug: Aerosolized 13 cis retinoic acid plus Vitamin D; Aerosolized All trans retinoic acid plus Vitamin D · For: Post COVID-19 Anosmia (Loss of Smell)
Sites: Foshan, China; Kafr ash Shaykh, Egypt; Riyadh, Saudi Arabia
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With NeuroblastomaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00026312 · 1,449 participants · Start Oct 26, 2001 · Primary completion Jan 12, 2012
Drug: Aldesleukin; Dinutuximab and 2 more · For: Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma and 3 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Phoenix, Arizona · 197 sites in all
- Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword?Pivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT04623385 · 1,000 participants (planned) · Start Nov 2020 · Primary completion Dec 2020
Drug: The standard therapy · For: Covid19
- Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular AcnePivotal-lookingCompleted
Cipher Pharmaceuticals Inc.Industry
NCT00975143 · 925 participants · Start Sep 2009 · Primary completion May 2011
Drug: CIP-Isotretinoin; Isotretinoin · For: Severe Nodular Acne
Sites: Birmingham, Alabama; Hot Springs, Arkansas; Fremont, California · 49 sites in all
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)Pivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03126916 · 750 participants (planned) · Start May 14, 2018 · Primary completion Sep 30, 2030
Drug: Busulfan; Carboplatin and 13 more · For: Ganglioneuroblastoma; Ganglioneuroblastoma, Nodular; Neuroblastoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 164 sites in all
- European Low and Intermediate Risk Neuroblastoma ProtocolPivotal-lookingCompleted
Instituto de Investigacion Sanitaria La FeAcademic, hospital or other
NCT01728155 · 685 participants · Start Jan 1, 2011 · Primary completion Dec 31, 2022
Drug: chemotherapy · For: LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES
Sites: Clayton, Australia; Nedlands, Australia; Sydney, Australia · 98 sites in all
- Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk NeuroblastomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00567567 · 665 participants · Start Nov 5, 2007 · Primary completion Feb 27, 2015
Drug: Carboplatin; Cisplatin and 9 more · For: Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma and 3 more
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 190 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- depression1,247
- pregnancy1,042
- exposure during pregnancy1,034
- abortion induced805
- product dose omission issue689
- headache680
- adverse drug reaction673
- dry skin672
- arthralgia658
- drug ineffective604
- suicidal ideation603
- mood altered534
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 124 |
| 2005 | 209 |
| 2006 | 355 |
| 2007 | 491 |
| 2008 | 766 |
| 2009 | 503 |
| 2010 | 492 |
| 2011 | 276 |
| 2012 | 383 |
| 2013 | 357 |
| 2014 | 345 |
| 2015 | 512 |
| 2016 | 769 |
| 2017 | 537 |
| 2018 | 616 |
| 2019 | 596 |
| 2020 | 864 |
| 2021 | 1,075 |
| 2022 | 1,580 |
| 2023 | 1,738 |
| 2024 | 2,348 |
| 2025 | 2,353 |
| 2026 | 1,366 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Absorica (Isotretinoin)
2024 spending
$40K
Beneficiaries
18
24 claims
Per beneficiary
$2,232
$36.41 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $235,354 |
| 2021 | $163,699 |
| 2022 | $93,009 |
| 2023 | $76,072 |
| 2024 | $40,180 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Guidelines of care for the management of acne vulgaris.
Reynolds RV, Yeung H, Cheng CE, et al. · J Am Acad Dermatol 2024 · Practice Guideline, Systematic Review
- Acne and the cutaneous microbiome: A systematic review of mechanisms and implications for treatments.
Podwojniak A, Tan IJ, Sauer J, et al. · J Eur Acad Dermatol Venereol 2025 · Systematic Review
- A systematic review and network meta-analysis of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris.
Mavranezouli I, Daly CH, Welton NJ, et al. · Br J Dermatol 2022 · Systematic Review, Network Meta-Analysis
- Adverse Events in Isotretinoin Therapy: A Single-Arm Meta-Analysis.
Kapaa J, Lewandowska J, Placek W, et al. · Int J Environ Res Public Health 2022 · Meta-Analysis, Review
- Systematic review of low-dose isotretinoin for treatment of acne vulgaris: Focus on indication, dosage, regimen, efficacy, safety, satisfaction, and follow up, based on clinical studies.
Sadeghzadeh-Bazargan A, Ghassemi M, Goodarzi A, et al. · Dermatol Ther 2021 · Systematic Review
- Wrinkles.
Manríquez JJ, Majerson Gringberg D, Nicklas Diaz C · BMJ Clin Evid 2008 · Systematic Review
Sponsor: Sun Pharm Inds INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.